Trial Profile

Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria (AHP)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 22 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Givosiran (Primary)
Indications Hepatic-porphyria
Focus Expanded access; Therapeutic Use
Sponsors Alnylam Pharmaceuticals

Most Recent Events

10 Mar 2021 Status changed from recruiting to completed.
12 Aug 2019 New trial record
05 Aug 2019 According to an Alnylam Pharmaceuticals media release, the company has initiated this study. This will support requests by Health Care Providers for pre-approval access for acute hepatic porphyria (AHP) patients.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com